Safety and Pharmacokinetics of Y-4 Tablets in Healthy Subjects
Status:
RECRUITING
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole.
The primary objective is to evaluate the safety and tolerability of Y-4 tablets in Chinese healthy adult subjects after single- and multiple-dose.
The secondary objective is to characterize the pharmacokinetics (PK) of pregabalin and riluzole in Chinese healthy adult subjects after single- and multiple-dose of Y-4 tablets.